Play it again, Celldex

Investors flocked to Celldex Therapeutics Inc. (NASDAQ:CLDX) after the company announced a cancer immunotherapy partnership with Bristol-Myers Squibb Co. (NYSE:BMY). Buysiders may be hoping the narrow nature of the BMS deal means the biotech isn't done with its deal-making.

Celldex spiked $3.34 (27%) to $15.74 last Wednesday after unveiling an exclusive deal to run a trial of BMS's anti-PD-1 mAb nivolumab with Celldex's anti-CD27 varlilumab (CDX-1127). In 4Q14, Celldex will begin a Phase I/II trial of the combination in up to 200 patients with multiple tumor types...